MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Potential BlockBuster Technology and/or Business Model
Nucleome Therapeutics Limited
Organization & Developments: Nucleome Therapeutics
Parents
Nucleome Therapeutics Limited
Children
2022: Nucleome Attracts Big Pharma Investment to Explore Genetic "Dark Matter"
Dark matter contains 90 per cent of disease-linked genetic changes, but most have no function currently ascribed to them and shedding light on them could provide important avenues for drug discovery
Nucleome combines 3D genome technology with machine learning to cast light on biological dark matter, which makes up over 98 percent of the human genome
Jumps
Finance & Acquisitions: Nucleome Therapeutics
Key People: Nucleome Therapeutics